The expression of P-glycoprotein was investigated immunohistochemically in 26 brain tumor tissues and compared with the findings of technetium-99m methoxyisobutylisonitrile single photon emission computed tomography ( 99m Tc-MIBI SPECT) to clarify the effect of P-glycoprotein on the diagnostic accuracy. P-glycoprotein labeling index of both tumor cells and vascular endothelial cells showed no clear relationship with the findings of 99m Tc-MIBI SPECT imaging. Expression of P-glycoprotein has no effect on the diagnostic accuracy of 99m Tc-MIBI SPECT.
Introduction
P-glycoprotein is a membrane protein that excretes some anti-cancer agents from tumor cells into the extracellular space. The multi-drug resistance 1 gene that encodes P-glycoprotein is overexpressed in many types of tumor cells, so an excess of Pglycoprotein is produced in these tumor cells. 9, 12) Technetium-99m methoxyisobutylisonitrile ( 99m Tc-MIBI) may be excreted from tumor cells by Pglycoprotein. 1, 3, 16) An in vitro study demonstrated that 99m Tc-MIBI was accumulated less in strains of fibroblasts positive for P-glycoprotein than in strains negative for P-glycoprotein. 3, 16) Therefore, clinical cases of malignant glioma not demonstrated by 99m Tc-MIBI single photon emission computed tomography (SPECT) were probably secreting Pglycoprotein. 1) SPECT with 99m Tc-MIBI is useful for assessing the malignancy of brain tumor. 2, 3, 15) SPECT with 99m Tc-MIBI provides clearer images and delineation of the tumor than SPECT with thallium-201 chloride. However, the influence of the expression of P-glycoprotein on 99m Tc-MIBI SPECT has not been fully established.
The present study examined the expression of Pglycoprotein in 26 brain tumor specimens for comparison with the findings of 99m Tc-MIBI SPECT to clarify the effect of P-glycoprotein on tumor imaging using 99m Tc-MIBI SPECT.
Materials and Methods
I. Patient population Thirty-four patients underwent 99m Tc-MIBI SPECT before surgical removal of brain tumor. Immunohistochemical examination of paraffinembedded materials was performed in 22 patients, nine males and 13 females aged 22 to 80 years (mean 48.4 years). Four patients also underwent 99m Tc-MIBI SPECT at recurrence, so a total of 26 SPECT images and 26 surgical specimens were evaluated. The histological diagnosis was astrocytoma grade 2 in seven cases, mixed oligoastrocytoma in three, dysembryoplastic neuroepithelial tumor in one, astrocytoma grade 3 (anaplastic astrocytoma) in six, glioblastoma in six, metastasis from lung adenocarcinoma in one, and radiation necrosis in two. There were 14 initial cases and 12 recurrent cases. Nine patients were given chemotherapy before 99m Tc-MIBI SPECT. Four patients were treated with in- II. 99m Tc-MIBI SPECT 99m Tc-MIBI SPECT was performed a few days before the surgical removal of the tumor. Early and delayed SPECT images were obtained immediately and 3 hours after the intravenous injection of 370 MBq of 99m Tc-MIBI solution. SPECT data were acquired for 30 minutes using a Headtome set 050 (Shimadzu, Kyoto). SPECT images were reconstructed with Ramp and Butterworth filtering, and the absorption was corrected using reported methods. 11) Regions of interest (ROIs) were selected in the tumor area and contralateral normal white matter on the SPECT images. MIBI indexes were calculated from the ratio of tumor ROI to contralateral normal ROI.
III. Histological examination
Surgical specimens were embedded and fixed in 10% formaldehyde solution. Histological diagnoses were made from the prepared specimens stained with hematoxylin and eosin. The paraffin-embedded tissues were dewaxed in xylene and rehydrated by passing through a 100-70% ethanol gradient for 3 minutes. After quenching, specimens were incubated with the monoclonal antibody to P-glycoprotein CLA51/1 (Medac Diagnostika, Hamburg, Germany) overnight at 409 C. This antibody is known to show stable staining with paraffin-embedded materials. 19) The specimens were developed by immunoperoxidase sandwich staining using a LSAB kit (DAKO, Carpinteria, Calif., U.S.A.). The P-glycoprotein labeling index of tumor cells was calculated as the mean percentage of positive tumor cells in three view fields and more than 1000 cells were counted. The P-glycoprotein labeling index of the vascular endothelial cells was calculated in the same manner. Cutoff points were determined based on the median expression of P-glycoprotein among all specimens examined.
Results

I. P-glycoprotein labeling and MIBI indexes of tumor cells
The P-glycoprotein labeling index of tumor cells ranged from 0% to 10.2%, with a mean value of 3.48% and a median value of 2.1%. Tumors with a labeling index of more than 2% were defined as PG positive. There were 14 PG positive and 12 PG negative cases (Table 1) . No differences between the PG positive and negative groups were found in age, sex, or diagnosis, except for the cases of radiation necrosis in the PG positive group.
Among the 14 initial cases, five were PG positive and nine were PG negative. Among the 12 recurrent cases, nine were PG positive and three were PG negative. PG positive cases were significantly more common among recurrent cases (Chi-square test, p º 0.001). The labeling index of recurrent cases (mean 5.37 ± 3.70) was significantly greater than that of initial cases (mean 1.86 ± 2.19) (Student's ttest, p º 0.01).
All cases except for those of radiation necrosis Neurol Med Chir (Tokyo) 42, August, 2002 P-glycoprotein and 99m Tc-MIBI SPECT were divided into low and high malignancy groups, based on the clinical and histological diagnoses. The low malignancy group included astrocytoma or mixed oligoastrocytoma, and the high malignancy group included anaplastic astrocytoma, glioblastoma, and metastasis. The early and delayed MIBI indexes of the low and high malignancy groups in the PG positive and negative groups are compared in Table 2 . The high malignancy group showed significantly higher early and delayed MIBI indexes than the low malignancy group in the PG negative group (Student's t-test, p º 0.05). The high malignancy group tended to show higher MIBI indexes than the low malignancy group in the PG positive group, but the difference was not statistically significant. The early and delayed MIBI indexes of PG positive group were higher than those of the PG negative group, but only the low malignancy group showed a statistically significant difference in delayed MIBI index (Student's t-test, p º 0.05). The analyses were repeated with the subgroups of initial cases, and the same results were obtained. Statistical analysis of the MIBI index in the subgroups of recurrent cases was not possible due to the distribution of the cases.
No high malignancy tumor showed negative 99m Tc-MIBI uptake but positive PG expression. Two cases which showed negative 99m Tc-MIBI uptake and positive PG expression were low malignancy tumors.
99m Tc-MIBI SPECT was performed twice, at initial diagnosis and at recurrence, in four cases. There was no histological transformation at recurrence except for one case of anaplastic astrocytoma at initial diagnosis that became radiation necrosis at recurrence. Two cases were treated with radiation and chemotherapy with ACNU or PAV regimen at initial MIBI examination. All four cases received radiation and chemotherapy with ACNU or PAV regimen at recurrence. All four cases showed an increase in Pglycoprotein labeling index and MIBI indexes at recurrence.
II. P-glycoprotein labeling and MIBI indexes of vascular endothelial cells
The P-glycoprotein labeling index of vascular endothelial cells ranged from 0% to 53.8%, with a mean value of 14.5% and a median value of 4.4%. Cases with a labeling index for vascular endothelial cells of more than 4% were defined as PG positive. The PG positive group included 13 cases and the PG negative group included 13 (Table 3) . No differences were observed between the PG positive and negative groups with regard to age, sex, or diagnosis, except for the cases of radiation necrosis in the PG negative group.
Among the 14 initial cases, six were PG positive and eight were PG negative. Among the 12 recurrent cases, seven were PG positive and five were PG negative. The mean labeling index was 11.9 ± 17.0 for initial cases and 15.0 ± 19.7 for recurrent cases, with no significant difference.
The early and delayed MIBI indexes of the low and high malignancy groups in the PG positive and negative groups are compared in Table 4 . No differences were statistically significant. The analyses were repeated with the subgroups of initial and recurrent cases, and the same results were obtained.
99m Tc-MIBI SPECT was performed twice in four cases. Three cases showed an increase in Pglycoprotein labeling index at recurrence, and one case of radiation necrosis showed decrease.
III. Correlation of P-glycoprotein labeling and MIBI indexes
The correlations between P-glycoprotein labeling indexes and MIBI indexes were analyzed. Early 
Discussion
The present study found a higher P-glycoprotein labeling index in recurrent tumors. The high malignancy group showed higher early and delayed MIBI indexes than the low malignancy group, but no such tendency was found with the P-glycoprotein labeling index. In our series, no case of false negative 99m Tc-MIBI SPECT finding due to high expression of Pglycoprotein was observed. Our results indicate that the expression of P-glycoprotein has no obvious effect on the diagnostic accuracy of 99m Tc-MIBI SPECT.
Functional imaging of P-glycoprotein is possible using 99m Tc-MIBI SPECT both in vitro and in vivo. 4, 16, 18) Under controlled conditions such as the same tumor viability or blood supply, the total amount of P-glycoprotein may be directly related to the findings of 99m Tc-MIBI SPECT imaging, but many factors influence the findings in a clinical setting. The amount of P-glycoprotein is only one of these factors, whereas the most important may be tumor viability or the malignant potential of the tumor cells. The amount of 99m Tc-MIBI taken up into tumor cells is proportional to the function of calci-P-glycoprotein and 99m Tc-MIBI SPECT um-dependent sodium potassium adenosine triphosphatase on the cell membrane of the tumor cells. 8, 17) However, we could not detect any influence of Pglycoprotein on 99m Tc-MIBI SPECT.
The CLA51/1 monoclonal antibody of Pglycoprotein is known to show stable staining of paraffin-embedded materials. 19) There are several commercially available monoclonal antibodies for Pglycoprotein. Some monoclonal antibodies do not cause stable staining of paraffin-embedded materials. 5, 10, 13, 14, 21) Many investigations of P-glycoprotein expression in brain tumors were conducted using such unstable monoclonal antibodies and fresh frozen tumor samples. 5,10,13,14,21) P-glycoprotein labeling indexes using fresh frozen tumor samples varied from 0-20%, and agree with the P-glycoprotein labeling indexes in our study. There may be subtypes of P-glycoproteins recognized by different monoclonal antibodies. Details of the structure and the function of P-glycoprotein detected by various monoclonal antibodies should be further investigated.
Blood vessels in normal specimens or benign glioma specimens are generally reported to stain positively for P-glycoprotein. 10, 14, 22) However, Pglycoprotein expression in the vascular endothelial cells of anaplastic primary brain tumors is heterogeneous or absent. 10) In our study, the vascular endothelial cells in some cases in the low malignancy group did not express P-glycoprotein, whereas some cases in the high malignancy group showed high labeling indexes for P-glycoprotein. Our results indicate that P-glycoprotein labeling index of endothelial cells is not directly related to the malignancy of the tumor. Also, the 99m Tc-MIBI index had no relationship with the P-glycoprotein labeling index of endothelial cells.
Only some tumor cells are positive for Pglycoprotein. 10 ) Examination of histological specimens cannot clarify the relationship between Pglycoprotein expression and the clinical functions of P-glycoprotein on blood vessels or tumor cells. The capillary endothelium acts as the blood-brain barrier in normal brain, but does not in malignant glioma, although both express P-glycoprotein. 20) The relationship between expression of P-glycoprotein by the capillary endothelium or tumor cells and the function of P-glycoprotein remains unclear. Consequently, the clinical significance of P-glycoprotein expression is also unknown. However, expression of P-glycoprotein in tumor cells is directly related to the uptake of 99m Tc-MIBI in vitro and in vivo. 16, 18) Therefore, the P-glycoproteins in blood vessels have little effect on the uptake of 99m Tc-MIBI.
The P-glycoprotein labeling indexes of both tumor cells and vascular endothelial cells showed no clear relationship with 99m Tc-MIBI uptake. The presence of P-glycoprotein in tumor tissue had little influence on 99m Tc-MIBI SPECT imaging. Therefore, the diagnostic accuracy of 99m Tc-MIBI SPECT is not affected by expression of P-glycoprotein.
